Cardiovascular OCT Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Cardiovascular OCT Imaging Market Trends and Insights

Increasing Use of Intravascular Imaging in Complex PCI

The cardiovascular OCT imaging market is gaining traction as OCT-guided PCI becomes more established for complex coronary lesions. A 2025 network meta-analysis of 17 randomized trials involving 13,751 patients found that OCT guidance reduced major adverse cardiovascular events by 37% compared with angiography alone, with consistent outcomes across chronic total occlusions, left main disease, bifurcations, and severe calcification.^{[1]2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Diagnosis and Management of Acute Coronary Syndromes,” npj Cardiovascular Health, nature.com.} The 2025 ECLIPSE trial enrolled 2,005 patients with severely calcified lesions and reported a 1-year target vessel failure rate of 7.7% with OCT guidance, compared with 13.2% with angiography guidance alone.^{[2]“Global, Regional, and National Burden of Cardiovascular Diseases,” Journal of the American College of Cardiology, jacc.org.} As complex PCI procedures involving multivessel disease, multiple stents, and heavily calcified lesions increase, hospitals have stronger incentives to invest in imaging systems and operator training.

AI-Assisted Stent Sizing and Optimization

Artificial intelligence is expanding the potential user base for the cardiovascular OCT imaging market by reducing the interpretation burden on less experienced physicians. A 2025 study found that Abbott’s Ultreon AI software improved physician accuracy in selecting stent diameter by a factor of 2.83 compared with conventional OCT software and reduced variation in landing-zone assessment.^{[3]“IVUS, OCT, or Angiography as Guidance for PCI in Complex Coronary Artery Lesions: Network Meta-Analysis of Randomized Controlled Trials,” JACC: Cardiovascular Interventions, sciencedirect.com.} Abbott received FDA 510(k) clearance and CE Mark for Ultreon 3.0 on April 28, 2026, offering automated plaque tissue characterization, stent-size recommendations, and a 1-second pullback using low or zero contrast. Standardized workflows, integrated reporting, co-registration, and software updates can help hospital networks improve consistency across catheterization laboratories.

Rising Cardiovascular Disease and Complex Lesion Burden

The cardiovascular OCT imaging market is supported by the rising cardiovascular disease burden and increasing clinical complexity associated with an aging population. The Global Burden of Disease 2023 study reported 626 million prevalent cardiovascular disease cases in 2023, compared with 311 million in 1990, while ischemic heart disease remained the leading contributor to cardiovascular disability-adjusted life years. A 2025 pooled analysis of four randomized trials involving 5,603 patients found that OCT-guided PCI reduced major adverse cardiovascular events, cardiac death, myocardial infarction, and stent thrombosis compared with angiography alone. The analysis reported a 57% reduction in cardiac death, strengthening the clinical case for OCT use in higher-risk procedures.

Saline-Compatible and Low-Contrast OCT Workflows

Low-contrast and saline-compatible workflows address a key barrier to OCT use in patients with renal impairment. Abbott stated in April 2026 that 25% of patients with coronary artery disease had comorbid chronic kidney disease, making contrast exposure a significant consideration during imaging-guided PCI. A prospective multicenter study presented at TCT 2025 found no meaningful difference between heparinized saline and iodinated contrast in quantitative OCT measurements, including minimum lumen areas of 5.33 ± 2.48 mm² and 5.36 ± 2.52 mm², respectively. Built-in low-contrast capabilities in Ultreon 3.0 and Gentuity’s HF-OCT system can expand OCT adoption, although broader uptake depends on operator training and catheterization laboratory protocol updates.

Contrast Use and Renal-Risk Concerns in Conventional OCT Workflows

The cardiovascular OCT imaging market faces a gap between evidence supporting saline use and catheterization laboratory protocols. Complex procedures involving multiple OCT pullbacks can require more than 200 mL of iodinated contrast when combined with diagnostic angiography, increasing acute kidney injury risk in patients with renal impairment, diabetes, or heart failure. Most fellowship programs do not offer standardized saline-based OCT training, limiting operator familiarity with the workflow. Hospitals may continue to avoid OCT for patients who could benefit from detailed imaging until guideline updates, vendor-supported education, and local protocols establish contrast-minimizing practices.

Procedure-Time, Training, Reimbursement, and Governance Variability

The cardiovascular OCT imaging market also faces procedure-time, radiation exposure, and operator-training constraints, particularly in lower-volume hospitals and developing healthcare systems. Japan reimburses intravascular imaging as part of standard PCI practice and expanded OCT reimbursement following the OCCUPI trial, while many countries in South Asia, the Middle East, and South America lack dedicated OCT billing codes. Outside North America and Western Europe, payer-policy changes can take 3 to 5 years after guideline updates. FDA 510(k), CE Mark requirements under EU MDR, and approvals from India’s CDSCO and China’s NMPA can extend market-entry timelines, particularly for platforms with AI-enabled software.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Catheter Replacement Cycles Reshape Revenue Mix

Intravascular OCT imaging systems held 58.66% of the cardiovascular OCT imaging market in 2025, reflecting the high upfront investment required for catheterization laboratory hardware. Hospitals typically procure consoles with multiyear service agreements, software road maps, and clinical training, making vendor relationships and system integration key purchasing considerations. The installed base results in long replacement cycles and high switching costs. OCT imaging catheters are the fastest-growing product category and are projected to expand at a 10.12% CAGR through 2031, supported by PCI procedure volumes and recurring demand.

Gentuity received FDA 510(k) clearance in January 2025 for the Vis-Rx PRIME micro-imaging catheter for use with its HF-OCT imaging system. Its 1.8F profile enables imaging of severely stenotic vessels without pre-dilation and provides 100 mm of coronary coverage in 1 second. Accessories and consumables support connection and flushing workflows, with demand generally following catheter adoption. FDA classification distinguishes diagnostic intravascular catheters under 21 CFR 870.1200 from imaging systems under 21 CFR 892.1560, affecting software modification requirements and Predetermined Change Control Plan eligibility.

By Technology / Imaging Architecture: Hybrid Modalities Begin Disrupting the FD-OCT Baseline

Frequency-domain OCT and Fourier-domain OCT held a 47.76% share in 2025, supported by an established clinical evidence base and broad commercial availability. However, limited penetration through lipid-rich or heavily calcified plaque and the need for contrast flushing remain key limitations. High-frequency OCT is projected to grow at a 9.80% CAGR through 2031, driven by smaller catheter profiles and reduced vessel-preparation requirements. Optical frequency-domain imaging also improves imaging speed for larger-vessel assessment.

Gentuity’s HF-OCT system features a 1.8F catheter profile that images narrow lesions before pre-dilation, where conventional OCT catheters may require vessel preparation. Philips acquired SpectraWAVE in December 2025, adding the HyperVue system, which combines DeepOCT, near-infrared spectroscopy, and X1-FFR single-angiogram wire-free FFR technology. Conavi Medical received FDA 510(k) clearance in April 2026 for the Novasight Hybrid System, which supports co-registered, simultaneous IVUS and OCT imaging in a single pullback. These developments position the cardiovascular OCT imaging market toward integrated multimodal platforms.

By Application: ACS/MINOCA Anchors Volume While Stent Optimization Drives Outcomes Economics

Acute coronary syndrome and MINOCA assessment accounted for a 55.66% revenue share in 2025. OCT identifies culprit lesions when angiography shows non-obstructive coronary arteries, supporting MINOCA diagnosis. A 2025 meta-analysis of 45 studies involving 17,539 patients found acute pathological findings with OCT in 62% of MINOCA presentations. A 2025 multimodality study of 754 MINOCA patients found that OCT identified an ischemic cause in 45% of cases, including 43% of women, and detected a culprit lesion in 27% of patients with a normal angiogram.

Stent optimization is the fastest-growing application, with a projected 11.45% CAGR through 2031. The OCTIVUS trial enrolled 1,980 patients undergoing imaging-guided PCI and reported stent optimization in 48.3% of OCT-guided cases. The optimized group recorded a 2-year target vessel failure rate of 3.0%, compared with 7.6% in the non-optimized OCT group. These outcomes support the clinical and economic case for OCT in stent sizing, landing-zone selection, post-stenting assessment, and repeat-intervention risk reduction.

By End User: Hospitals Anchor the Market, Specialty Clinics Define the Growth Frontier

Hospitals and tertiary care centers held 53.56% of the cardiovascular OCT imaging market in 2025, reflecting the concentration of complex multivessel PCI procedures and the capital cost of OCT consoles. Cardiovascular service-line budgets, multiyear vendor relationships, and service contracts guide purchasing decisions. Switching vendors after installation can create significant cost and operational disruption. Abbott’s OPTIS Next and ILUMIEN platforms maintain a strong presence in U.S. and European hospitals, while ambulatory surgical centers are increasing demand for compact imaging systems.

Specialty cardiology clinics are projected to grow at a 10.56% CAGR through 2031. Smaller OCT console footprints reduce infrastructure requirements outside full-service hospitals, while expanding interventional cardiology credentials and case volumes support adoption. Academic and research institutes continue to influence clinical practice through investigator-led trials and fellowship training. ISO 13485 quality-management requirements also sustain vendor engagement through documented training and device-management processes.

Geography Analysis

North America held 39.44% of the cardiovascular OCT imaging market share in 2025, supported by established reimbursement systems, high catheterization laboratory capacity, and clinical trial participation. The United States performed more than 600,000 PCI procedures annually, and the 2025 U.S. guideline recommendation for intravascular imaging in complex lesions supported broader institutional adoption. Canada and Mexico were smaller contributors, while cardiac centers in Toronto and Montreal adopted practices aligned with U.S. clinical evidence. Europe was the second-largest regional market, led by Germany, the United Kingdom, and France, although reimbursement remained inconsistent despite the 2024 ESC Class I, Level A recommendation.

Asia-Pacific was the fastest-growing region, with the cardiovascular OCT imaging market projected to expand at a CAGR of 11.88% through 2031. Japan reimbursed intravascular imaging under its national health insurance system, and its 2025 clinical guidance provided OCT recommendations for calcium assessment and rotational atherectomy planning. China drove procedure-volume growth and saw the emergence of domestic OCT suppliers, while South Korea and India expanded catheterization laboratory capacity. However, uneven reimbursement, regulatory approvals, and operator training continued to create significant variation in adoption across the region.

The Middle East and Africa and South America represented smaller but improving opportunities for the cardiovascular OCT imaging market. Saudi Arabia’s Vision 2030 supported cardiac center installations in Riyadh and Jeddah, while Dubai expanded cardiac care infrastructure; South Africa led adoption in Sub-Saharan Africa, although reimbursement and training limitations persisted. Brazil led South American adoption through its public-private cardiology system and major cardiac centers in São Paulo and Rio de Janeiro, while Argentina had lower penetration. Market entry required compliance with ANVISA, INVIMA, and SAHPRA requirements, which could extend the introduction timeline for FDA- or CE-certified products.